Example: bankruptcy
Search results with tag "Benef"
E2C (R2) Step 5 Periodic benefit-risk evaluation report ...
www.ema.europa.euThe Periodic Benefit-Risk Evaluation Report (PBRER) described in this guideline is intended to be a common standard for periodic benef it-risk evaluation reporting on marketed products (including approved drugs that are under further study) among the ICH regions.
148 COAGULA BeneF D RECOMBINANT W IX TION …
www.fda.govprocedures was 85 ± , Coagulation Factor IX (Recombinant), is indicated for the control and ). Patients with factor IX inhibitors may be at an increased risk of